Produção Nacional
CURRENT USE AND OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION: BRAZILIAN SUMMARY SLIDES – 2024
2024; Volume: 5; Issue: 1 Linguagem: Inglês
10.46765/2675-374x.2024v5n1p228
ISSN2675-374X
AutoresAnderson João Simione, Cinthya Corrêa da Silva, Paula Moreira da Silva Sabaini, Antônio Vaz de Macedo, Heliz Regina A. Neves, Bruna Letícia da Silva Santos Geraldo, Monique Ammi, Flavia Ferreira da Costa, Valeria Viana, Adriana Mendes de Quadros Cavilha, Rosana Rocha Concilio, Vergílio Antônio Rensi Colturato, Phillip Scheinberg, Samir Kanaan Nabhan, Décio Lerner, Nelson Hamerschlak, Marcos Paulo Colella, George Maurício Navarro Barros, Alexandre Silvério, Adriana Seber, Yana Novis, Vanderson Rocha, Maria Cláudia Rodrigues Moreira, Cláudia Caceres Astigarraga, Liane Esteves Daudt, Maria Cristina Martins de Almeida Macedo, Ricardo Chiattone, Juliana Folloni Fernandes, Volney Assis Lara Vilela, Rodolfo Daniel de Almeida Soares, Gustavo Machado Teixeira, Celso Arrais‐Rodrigues, Roberto Luiz da Silva, Vaneuza Araújo Moreira Funke, Afonso Celso Vigorito, Leonardo Javier Arcuri, Jayr Schmidt Filho, Vinícius Campos de Molla, João Samuel de Holanda Farias, Ricardo Pasqüini, Carmem Bonfim, Abrahão Elias Hallack Neto, Rodolfo Calixto, Luís Fernando Bouzas, João Victor Piccolo Feliciano, Rafael Dezen Gaiolla, Marcelo Capra, Ângelo Atalla, Milton A. F. Aranha, Rony Schaffel, Gianne Donato Costa Veloso, Gustavo Bettarello, Andresa Lima Melo, Simone De Castro Resende Franco, Marcelo C. Pasquini, Fernando Barroso Duarte,
Tópico(s)Acute Myeloid Leukemia Research
ResumoThe development of the Brazilian Registry of Hematopoietic Cell Transplantation in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR) allowed for an assessment of the activity and general outcomes of transplants in Brazil. Here, we report an updated activity. Brazilian transplant centers report their data to the CIBMTR, using the FormsNet3 platform. Information returns to Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) through the Data Back to Centers (DBtC) tool. Data from patients who received an HCT from 2012 to 2023 from Brazilian centers were extracted from CIBMTR. Descriptive analysis was carried out by patient-, disease- and transplant-specific variables and overall survival analysis using Kaplan Meyer. A total of 12,230 patients were eligible for this study (5,573 autologous and 6,657 allogeneic transplants). The number of reporting centers increased from 40 to 44 during the period. The most common HCT indication in Brazil is AML for allogeneic HCT with 152 transplants year and multiple myeloma for autologous HCT with 245 transplants per year. Among allogeneic HCT, in the last 4 years, mismatched related donor was the main source of donors. Regarding the graft source for allogeneic transplants, BM was the most frequent among pediatric transplants, while PBSC was the most used in adults. Infections were the leading cause of death in the first 100 days after all types of transplants. Patients with acute leukemia who underwent HCT with advanced stage disease had lower survival rates compared to those at other stages. Despite the differences in the number of cases and follow-up time, the results in this study were similar to those presented in the United States (US) Summary Slides.
Referência(s)